Contributions of CuriousCallum

Contributions by CuriousCallum, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 144 edits includes activity predating the current log.

1. 01:42, 16 Jul 2026 (diff | hist) CagriSema 5,687 ±0 m attribute the mechanism claim to the review rather than stating it flatly
2. 03:00, 16 Jun 2026 (diff | hist) Amylin 5,795 ±0 attribute the potency comparison to the head-to-head trial rather than to two separate ones
3. 12:37, 16 Apr 2026 (diff | hist) International nonproprietary name 4,356 ±0 m ce per PP:MOS
4. 15:05, 14 Mar 2026 (diff | hist) Talk:Orforglipron 748 +157 /* Species selectivity */ reply
5. 10:50, 6 Mar 2026 (diff | hist) Talk:Peptide 537 +198 /* GLP-1 numbering */ new section
6. 00:28, 17 Feb 2026 (diff | hist) Receptor bias 4,477 ±0 m expand §The concept
7. 21:46, 9 Feb 2026 (diff | hist) Triple agonist 4,269 ±0 add the year of first marketing authorisation, with the regulator named
8. 08:48, 9 Feb 2026 (diff | hist) Survodutide 5,445 ±0 give the isoelectric point with the method it was determined by
9. 22:43, 2 Oct 2025 (diff | hist) Liraglutide 5,967 ±0 m rm duplicated pharmacokinetics — the same figures appear in the infobox
10. 15:28, 22 Sep 2025 (diff | hist) Amylin receptor agonist 5,245 ±0 m rm the equipotency claim — the cited paper does not make it
11. 01:17, 30 Aug 2025 (diff | hist) Dual incretin agonist 5,851 +485 m label the animal data as animal data in the sentence, not only in the section heading
12. 22:29, 28 Aug 2025 (diff | hist) Amylin 5,099 ±0 expand §Amyloid formation
13. 11:56, 23 Jun 2025 (diff | hist) Tirzepatide 7,922 +149 rm the equipotency claim — the cited paper does not make it
14. 09:31, 21 Apr 2025 (diff | hist) Dual incretin agonist 4,734 ±0 the lead claimed weekly dosing for a compound dosed daily; corrected
15. 14:01, 9 Apr 2025 (diff | hist) Cagrilintide 3,187 ±0 state the substitution in one-letter code as well, per PP:MOS
16. 07:38, 30 Mar 2025 (diff | hist) Triple agonist 3,428 ±0 m copyedit
17. 06:36, 29 Mar 2025 (diff | hist) Amylin receptor agonist 3,909 ±0 ce
18. 00:38, 14 Mar 2025 (diff | hist) Oral semaglutide 3,519 ±0 m the lead claimed weekly dosing for a compound dosed daily; corrected
19. 12:43, 5 Mar 2025 (diff | hist) Amino acid analysis 3,582 +961 rm the assertion that two laboratories must agree; they need not
20. 10:09, 4 Mar 2025 (diff | hist) Insulin syringe unit conversion 3,664 +124 add the reset control description
21. 21:52, 10 Feb 2025 (diff | hist) Lixisenatide 3,035 +99 state the substitution in one-letter code as well, per PP:MOS
22. 01:41, 6 Feb 2025 (diff | hist) Gastric emptying 4,636 ±0 the glucose-dependence of the insulinotropic effect deserves its own sentence
23. 08:30, 29 Jan 2025 (diff | hist) Glucagon 4,913 ±0 expand §Receptor and signalling
24. 04:10, 21 Nov 2024 (diff | hist) Liraglutide 3,273 ±0 the half-life in the lead was the terminal figure; label it as such
25. 09:31, 28 Sep 2024 (diff | hist) Insulin secretion 3,806 +1,094 name the enzyme responsible for the cleavage at the first mention
26. 19:41, 25 Sep 2024 (diff | hist) Glucagon 3,686 +34 m attribute the potency comparison to the head-to-head trial rather than to two separate ones
27. 07:52, 21 Jun 2024 (diff | hist) GLP-1 receptor agonist 1,642 ±0 m expand §Mechanism